HPC · Science Deep Dive 6 April 2026 · revised 2026-04-06

The Omega-3 Brain Science That Most Advice Gets Wrong.

DHA is the brain's indispensable structural fat, but supplementation only delivers cognitive benefits to those who are genuinely deficient. The wellness industry systematically ignores that distinction. Here is what the science actually says, and what to do with it.

Section: Bio-Performance
Reading time: 22 min read
Sources: 45 · reviewed

01The Ratio Inversion

The brain evolved inside a dietary ratio industry destroyed

For most of human evolution, the ratio of omega-6 to omega-3 fatty acids in the diet hovered around one to one.[1] That balance was not a health decision. It was a consequence of eating what was available: wild game, freshwater fish, leafy greens, insects. The brain evolved inside that ratio. Its membranes were built from it. Its signalling molecules were synthesised from it. Then, over roughly 150 years, industrial agriculture inverted the equation. Seed oils replaced animal fats. Grain-fed livestock replaced grass-fed. The omega-6 to omega-3 ratio in the modern Western diet now sits between ten-to-one and twenty-five-to-one.[1][41] The brain did not get a vote.

That shift matters because docosahexaenoic acid (DHA), the primary omega-3 in neural tissue, is not a vitamin the body can synthesise efficiently on its own. The liver can convert the plant-based precursor alpha-linolenic acid (ALA) into DHA, but the conversion rate in humans is roughly zero to four percent.[5] For practical purposes, DHA in the brain comes from what you eat or supplement, primarily marine sources. The global data on how much people actually consume is stark: 76% of the world's population falls below the recommended floor of 250 mg combined EPA and DHA per day.[6]

The result is not a crisis that announces itself. Omega-3 brain benefits are not like vitamin C deficiency, where scurvy makes the gap obvious. DHA shortfall is slow, structural, and silent. When it shows up at all, it appears as slightly less efficient membranes, marginally slower synaptic transmission, a brain that works but works with higher biological overhead.[2]

01 · The history

The omega-3 supplement industry has not helped. It spent decades making sweeping promises ("brain food," "cognitive boost," "mental clarity") while the clinical trial evidence tells a more complicated story. The largest and most rigorous randomised controlled trial on omega-3 and cognitive aging, the VITAL cognitive ancillary study, enrolled 4,218 adults over age 60 and gave them 840 mg of EPA plus DHA daily for up to three years.[27] The result: no difference in cognitive change rate across eight neuropsychological tests compared to placebo.

That null finding is not an outlier. A meta-analysis of 36 randomised controlled trials in cognitively healthy older adults found little or no effect of supplementation on cognition.[29] The positive associations (larger hippocampal volumes, lower dementia risk, better processing speed) come overwhelmingly from observational studies, where people who eat more fish also tend to exercise more, earn more, and have better healthcare. Population-level studies consistently see benefits that controlled trials have repeatedly failed to reproduce.[27][29]

The question is no longer whether omega-3 is important for the brain. The biochemistry is settled. The question is whether supplementing it in someone who already eats a reasonable diet does anything measurable, and for whom the answer might actually be yes.

02The Mechanism

The Molecular Architecture of a Fat-Dependent Brain

Every neuron in your brain is wrapped in a membrane made largely of fat. Not the storage fat that accumulates around the midsection, but phospholipid fat, a double layer of fatty acid chains that forms the structural boundary of every cell. DHA occupies a privileged position in that architecture. It is preferentially esterified into the sn-2 position of membrane phospholipids, the slot that most directly affects the membrane's physical behaviour.[2][11] And because DHA has six double bonds along its 22-carbon chain, more than almost any other fatty acid in biology, it bends. That bend creates space. The membrane becomes more fluid, more flexible, better able to accommodate the conformational shifts that receptors, ion channels, and transport proteins need to function.[5][8]

This is not a subtle effect. DHA accounts for approximately 40% of all polyunsaturated fatty acids in neuronal membranes.[7] When DHA levels drop, whether from dietary deficiency, aging, or competition from excess omega-6, the membrane stiffens. Receptor proteins sit in a less accommodating lipid environment. Signal transduction slows. Membrane fluidity, the physical property that determines how efficiently a neuron can receive and transmit a signal, declines.[8][10]

Membrane fluidity is not a metaphor. It is a measurable physical parameter that changes with DHA concentration, and it directly governs the speed and reliability of synaptic transmission, which is the foundation of every cognitive act.[12]

From dietary omega-3 to neural repair: DHA locks into the membrane phospholipid bilayer, is released by phospholipase A2, and is converted into specialised pro-resolving mediators, resolvins and protectins, that direct microglia to resolve neuroinflammation at nanomolar concentrations.

Diagram · HPC

The story does not end at the membrane. When DHA is released from phospholipids by the enzyme phospholipase A2, it enters a cascade that leads to one of the more significant molecular discoveries of the last two decades: the synthesis of specialised pro-resolving mediators, or SPMs.[7] These molecules, resolvins, maresins, and protectins, are not anti-inflammatory in the conventional sense. They do not suppress the immune response. They resolve it. They signal to microglia, the brain's resident immune cells, that the inflammatory episode is over and it is time to shift from attack mode to repair mode.[7][18]

The potency matters here. SPMs operate at nanomolar to picomolar concentrations, roughly a thousand times lower than the parent DHA and EPA compounds that generate them.[7] One SPM in particular, neuroprotectin D1 (NPD1), has been shown to suppress the pro-inflammatory cytokines interleukin-1β, tumour necrosis factor-α, and interleukin-6 while shifting microglia toward an anti-inflammatory phenotype.[7][15][16] In cerebrospinal fluid, resolvin D1 levels correlate positively with cognitive function in patients with early dementia.[7]

The SPM pathway explains something that puzzled researchers for years: why omega-3 supplementation often showed anti-inflammatory effects far larger than the modest changes in overall fatty acid composition would predict. The answer is amplification. DHA does not fight inflammation directly. It generates a molecular class that does the work at vanishingly small concentrations.[18]

03Evidence

Five Studies That Define the Omega-3 Brain Debate

01The claim

The single load-bearing finding

The hero study finds SMD 0.98 attention improvement.

The mechanistic case for omega-3 brain benefits is not in serious dispute. What is in dispute, and what defines the field's central tension, is whether supplementing omega-3 in real people produces measurable cognitive improvement. The answer depends on which evidence you prioritise. Observational studies, large prospective cohorts followed over years, consistently link higher omega-3 intake to lower cognitive decline and larger brain volumes.[21][30][31] Randomised controlled trials in healthy older adults, the gold standard for causal c

Pooled estimate

SMD 0.98

02How we measured

Grading the DHA evidence

Studies scored on design, sample, rigour, causality, replication.

The omega-3 field's defining tension is the gap between observational studies, where higher DHA tracks with better brain structure, and controlled trials, where supplementation benefits only those starting from genuine deficiency.

Rubric weights

Design/35

Sample/20

Rigour/15

Causality/15

Replication/15

03The spread

Heterogeneity across 5 studies

Effect sizes across the ranked studies.

The evidence hierarchy reveals a pattern the supplement industry prefers to ignore. Omega-3 is structurally essential, mechanistically active, and conditionally beneficial, but the conditions matter enormously. The 2022 VITAL ancillary study, the largest RCT on the topic, found zero cognitive benefit in 4,218 older adults taking 840 mg EPA+DHA daily for up to three years.[27] That study enrolled North Americans with generally adequate baseline nutrition. The positive results, Stonehouse's memory improvements and the dose-response meta-analysis's attention gains, emerged in populations with low

Spread

82 → 68 /100

Range of point estimates across ranked studies.

04What does not hold

Negative knowledge

What the evidence base does not support.

One emerging thread deserves mention, though it remains hypothesis-generating rather than proven. Carriers of the APOE-ε4 allele, the strongest genetic risk factor for Alzheimer's disease, appear to have impaired DHA transport across the blood-brain barrier.[21][34] The Framingham data showed that EPA was particularly beneficial for white matter preservation in APOE-ε4 carriers.[21] Early-phase trial data suggests that high-dose DHA supplementation can increase cerebrospinal fluid DHA levels in these carriers, but cognitive outcome data from the definitive trial rem

Consumer dose

The studies

5 trials. One pooled answer.

Below: the anchor study in full; then the forest plot at scale; then the supporting trials in ranked order.

01Anchor

, A systematic review and dose-response meta-analysis of omega-3 supplementation on cognitive function

Shahinfar Scientific Reports 2025 Meta-Analysis · Dose-Response · GRADE Assessment

The largest and most current dose-response meta-analysis of omega-3 and cognition, synthesising 58 randomised controlled trials through December 2024. It identified a non-linear dose-response relationship with an optimal window of 1,000–2,500 mg/day, finding significant improvements in attention, pe

Rubric breakdown

Design27/35

Sample18/20

Rigour11/15

Causality10/15

Replication8/10

Citations8/10

Total 82/100

The strongest studies, ranked by methodological weight.

Each scored 0–100 against a six-criterion rubric, tagged by design and year; the anchor leads.

Anchor (Rank 1) Supporting

Rank Authors & title Journal · Year Finding Score

Satizabal

, Association of red blood cell omega-3 fatty acids with MRI markers and cognitive function in midlife (Framingham Heart Study)

Neurology · 2022

In 2,183 dementia-free participants at mean age 46, higher red blood cell omega-3 index was associated with significantly larger hippocampal volumes and better abstract reasoning. EPA showed particular benefit in APOE-ε4 carriers for white matter hyperintensity reduction.[21]

75/100

Stonehouse

, DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial

American Journal of Clinical Nutrition · 2013

In 176 healthy adults aged 18–45, 1.16 g/day DHA for six months significantly improved working memory reaction time (P = 0.002). Women showed enhanced episodic memory (+0.28 SD); men showed faster working memory processing (−0.60 SD).[22]

78/100

Liao

, Efficacy of omega-3 PUFAs in depression: A meta-analysis

Translational Psychiatry · 2019

Across 26 RCTs (N = 2,160), omega-3 produced a small overall antidepressant effect. EPA-dominant formulations (≥60% EPA) showed substantially larger effects (SMD = −1.03) at doses ≤1 g/day. DHA-pure and DHA-dominant formulations showed no significant antidepressant effect.[23]

73/100

Joffre & Rey

, N-3 polyunsaturated fatty acids and the resolution of neuroinflammation

Frontiers in Pharmacology · 2019

Characterised the full cascade by which DHA and EPA generate resolvins, maresins, and protectins via LOX and CYP450 enzymes. Demonstrated that SPMs suppress neuroinflammatory cytokines and shift microglia to anti-inflammatory phenotype at concentrations far below the parent compounds.[7]

68/100

04Stakes

The Slow Costs of Structural Deficiency

Omega-3 deficiency does not produce a dramatic failure. It imposes a distributed tax: slower membranes, weaker plasticity, unresolved inflammation. The degradation of cognitive infrastructure happens over years, not days.

01 System 01 · System 01

Structural Integrity

The average American consumes roughly 72 mg of DHA per day, less than a third of the minimum recommended 250 mg.[4] The U.S. omega-3 index averages 2.7%, placing most of the population in the lowest tier globally. At this level, neuronal membranes operate with suboptimal fluidity, and the efficiency of every receptor-mediated signal is marginally reduced.[3][38]

72 mg

In practice

slower processing, mild difficulty concentrating, no obvious pathology

02 System 02 · System 02

Cognitive Trajectory

Observational data from 48 longitudinal studies (N = 103,651) associates higher dietary omega-3 intake with approximately 20% lower risk of cognitive decline and all-cause dementia.[30][31] This is a relative risk reduction from habitual diet, not from supplementation. RCTs have not replicated it. The gap between observational promise and trial performance remains the field's central unresolved question.

In practice

gradual cognitive slowing attributed to "normal aging" that may be partially addressable

System 03 · System 03

Mood Regulation

Among U.S. adults in NHANES 2011–2014, those with higher DHA blood levels had 59% lower odds of moderate-to-severe depressive symptoms. This is an association, not a causal claim.[34][35] EPA-dominant omega-3 formulas show modest antidepressant effects in diagnosed major depression (SMD = −0.28), but DHA alone does not demonstrate this benefit. The mood pathway runs through EPA, not DHA.[23]

2011 The mood pathway runs through EPA, not DHA.

In practice

low-grade mood instability, reduced stress tolerance, blunted affect

04 System 04 · System 04

Inflammatory Baseline

The modern omega-6:omega-3 ratio of 10–25:1 shifts the immune system's resting state toward pro-inflammatory signalling.[1][41] In omega-3 deficient states, microglial activation is prolonged, SPM synthesis is impaired, and the resolution phase of neuroinflammation is delayed.[7][16] This does not cause inflammation. It prevents inflammation from resolving efficiently.

In practice

persistent brain fog after illness, slow recovery from cognitive stress, fatigue disproportionate to exertion

05Protocol

An Evidence-Based Omega-3 Brain Protocol

Four steps derived from the dose-response literature, bioavailability research, and the baseline-dependence principle. The protocol targets the most common failure modes: wrong dose, wrong form, wrong expectation.

The protocol, as a sequence.

Baseline → Daily → With Food → Purpose

01 Step 01 · Baseline

Know Your Number

Measure your omega-3 index before supplementing. The test measures EPA+DHA as a percentage of red blood cell fatty acids. Target range: 8–11%. Below 4% indicates genuine deficiency where supplementation has the strongest evidence of benefit.[38][44]

Why

The entire evidence base shows that omega-3 supplementation benefits are concentrated in people with low baseline status. Without knowing your number, you are dosing blind.[27][20]

3 Measure your omega-3 index before supplementing. The test measures EPA+DHA as a

Common mistake

Supplementing without testing. Most people in Western countries assume they are deficient when some may have adequate intake from diet alone.

02 Step 02 · Daily

Dose Within the Window

Take 1,000–2,000 mg combined EPA+DHA per day. This sits within the optimal dose range identified by the 2025 meta-analysis. Higher doses do not linearly increase benefit, the dose-response relationship is non-linear and benefits plateau or may decrease above 2,500 mg/day.[20][43]

Why

The dose-response curve is inverted-U for some cognitive domains, episodic memory, for instance, showed diminishing returns above the optimal range. More is not better past the threshold.[20]

1,000–2,000 mg Take 1,000–2,000 mg combined EPA+DHA per day. This sits within the optimal dose

Common mistake

Taking 3,000–4,000 mg daily on the assumption that more is more. The science does not support mega-dosing for cognitive benefit.

03 Step 03 · With Food

Choose the Right Form

Use triglyceride-form omega-3, taken with a fat-containing meal. Triglyceride forms achieve approximately 50% higher plasma EPA+DHA levels than ethyl ester equivalents. Ethyl ester absorption drops to roughly 20% when taken fasted but rises to 60% with a high-fat meal.[39]

Why

Form and timing determine how much of what you swallow actually reaches your bloodstream. Many clinical trials showing null results used ethyl ester forms at inadequate doses, a confound rarely disclosed.[39]

3 Use triglyceride-form omega-3, taken with a fat-containing meal. Triglyceride fo

Common mistake

Taking fish oil capsules on an empty stomach. Absorption of ethyl ester forms drops by two-thirds without dietary fat.

04 Step 04 · Purpose

Match the Fatty Acid to the Goal

For cognitive and structural goals, prioritise DHA. For mood and anti-inflammatory goals, prioritise EPA. The omega-3 brain literature is not about a single molecule, DHA governs membrane structure and plasticity; EPA governs inflammation resolution and mood regulation. Most supplements blend both, but the ratio matters.[5][23]

Why

Liao et al. (2019) demonstrated that EPA-dominant formulations (≥60% EPA) drove antidepressant effects while DHA-pure formulations did not. Conversely, DHA is the structural fatty acid, the brain contains 250–300× more DHA than EPA.[23][5]

3 For cognitive and structural goals, prioritise DHA. For mood and anti-inflammato

Common mistake

Using a high-DHA supplement for mood support, or a high-EPA supplement expecting structural brain benefits. The fatty acids have different primary roles.

Operational logic

The protocol above is deliberately conservative. It does not promise cognitive enhancement. It does not claim to prevent dementia. It matches what the dose-response literature, the baseline-dependence findings, and the bioavailability research actually support.[20][38][39] The science supports omega-3 supplementation as a deficit-correction strategy, not a performance-enhancement intervention. For someone with an omega-3 index of 2.7%, the U.S. average, bringing that number into the 8–11% range represents a genuine shift in the lipid environment available to the brain.[3][38] For someone already at 8%, additional supplementation is unlikely to produce measurable cognitive change.

That distinction is the entire point. Omega-3 is not a nootropic. It is a building material. Supplementing it when the building already has enough achieves nothing. Supplementing it when the building is running short changes the structural conditions under which every cognitive process operates.

---

06Verdict

The verdict.

"Supplementing omega-3 without knowing your baseline is like refuelling a car without checking the gauge.", Editorial synthesis, HPC Science Deep Dive (2026)

Bottom line

The brain does not need more omega-3 advice. It needs the right amount of the right fat, and the honesty to admit that for some people, that amount is already on their plate.

The practical takeaway is not that omega-3 does not matter. It matters at the level of membrane architecture, synaptic signalling, and neuroinflammation resolution.[7][8][2] The gap between biological necessity and supplementation benefit is wider than the industry admits. Most of the world is genuinely short on DHA.[6] Most clinical trials that found no benefit were conducted in populations that were not particularly short on DHA.[27] When those two facts are placed side by side, the contradiction dissolves into specificity.

The whole argument, on one axis

Same family. Different jobs.

01Claim

Essential structure, conditional supplement

DHA is the brain's dominant structural omega-3, comprising over 90% of neural omega-3 content and governing membrane fluidity, synaptic plasticity signalling, and neuroinflammation resolution. The mechanism is settled biochemistry, not a wellness hypothesis.[2][7]

02Consequence

Deficiency is silent and widespread

Three in four people globally fall below recommended intake. The U.S. omega-3 index averages 2.7% against a target of 8–11%. Suboptimal DHA status degrades cognitive infrastructure gradually, without producing a single diagnosable symptom until the deficit is years deep.[3][6][38]

03Lever

Test, then target

Measure your omega-3 index. If below 4%, supplement 1,000–2,000 mg EPA+DHA daily in triglyceride form with food. Match DHA to structural goals and EPA to mood goals. If your index is already 8%+, additional supplementation is unlikely to produce measurable cognitive benefit.[20][38][39]

07Bibliography

45 sources · ~6h est. corpus read · 45 visible

Meta · 3 Review · 5 Cohort · 3 Journal · 34

Type

Sort

01 Journal

Simopoulos, A. P2011

Evolutionary aspects of diet: the omega-6/omega-3 ratio and the brain

Molecular Neurobiology44(2) · 203–215

doi: 10.1007/s12035-010-8162-0
02 Journal

Weiser, M. J., Butt, C. M., & Mohajeri, M. H2016

Docosahexaenoic acid and cognition throughout the lifespan

Nutrients8(2)

doi: 10.3390/nu8020099
03 Journal

Torrissen, M., et al2025

Global variations in omega-3 fatty acid status and omega-6:omega-3 ratios: insights from >500,000 whole-blood dried blood spot samples

Lipids in Health and Disease2944-025

doi: 10.1186/s12944-025-02676-6
04 Journal

Papanikolaou, Y., et al2014

U.S. adults are not meeting recommended levels for fish and omega-3 fatty acid intake

Nutrition Journal1475-2891

doi: 10.1186/1475-2891-13-31
05 Review

Dyall, S. C2015

Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA

Frontiers in Aging Neuroscience

doi: 10.3389/fnagi.2015.00052
06 Cohort

Global survey data2025
07 Journal

Joffre, C., Rey, C., & Layé, S2019

N-3 polyunsaturated fatty acids and the resolution of neuroinflammation

Frontiers in Pharmacology

doi: 10.3389/fphar.2019.01022
08 Journal

Wu, A., Ying, Z., & Gomez-Pinilla, F2008

DHA dietary supplementation enhances the effects of exercise on synaptic plasticity and cognition

Neuroscience155(3) · 751–759

doi: 10.1016/j.neuroscience.2008.05.061
09 Journal

Bhatia, H. S., et al2011

Omega-3 fatty acid deficiency during brain maturation reduces neuronal and behavioral plasticity in adulthood

PLoS One6(12)

doi: 10.1371/journal.pone.0028451
10 Journal

Omega-3 and -6 fatty acids alter the membrane lipid composition and vesicle size to regulate exocytosis2024

*ACS Chemical Neuroscience*

ACS Chemical Neuroscience

doi: 10.1021/acschemneuro.3c00741
11 Journal

Brain docosahexaenoic acid uptake and metabolism2018

*Progress in Lipid Research*, 69, 1–16

Progress in Lipid Research1–16

doi: 10.1016/j.plipres.2017.12.003
12 Journal

Vancassel, S., & Aïd, S2007

DHA involvement in neurotransmission process

OCL, Oilseeds and Fats, Crops and Lipids14(3–4) · 3–4
13 Review

0
14 Journal

Cutuli, D2017

Functional and structural benefits induced by omega-3 polyunsaturated fatty acids during aging

Current Neuropharmacology15(4) · 534–542

doi: 10.2174/1570159X14666160614091311
15 Journal

Omega-3 polyunsaturated fatty acids suppress the inflammatory responses of LPS-stimulated mouse microglia by activating SIRT1 pathways2017

*Biochimica et Biophysica Acta*, 1862(8), 914–925

Biochimica et Biophysica Acta1862(8) · 914–925

doi: 10.1016/j.bbalip.2017.02.013
16 Journal

Brain omega-3 polyunsaturated fatty acids modulate microglia cell number and morphology in response to amyloid-β2016

*Journal of Neuroinflammation*, 13(1), 163

Journal of Neuroinflammation13(1) · 2974-016

doi: 10.1186/s12974-016-0721-5
17 Journal

Role of polyunsaturated fatty acids in human brain structure and function across the lifespan2017

*Prostaglandins, Leukotrienes and Essential Fatty Acids*, 136, 23–33

Prostaglandins, Leukotrienes and Essential Fatty Acids23–33

doi: 10.1016/j.plefa.2017.05.001
18 Journal

Omega-3 polyunsaturated fatty acids protect against inflammation through production of LOX and CYP450 lipid mediators2021

*Molecular Psychiatry*, 26(12), 6730–6745

Molecular Psychiatry26(12) · 6730–6745

doi: 10.1038/s41380-021-01160-8
19 Journal

The dietary ligands omega-3 fatty acid endocannabinoids and short-chain fatty acids prevent cytokine-induced reduction of human hippocampal neurogenesis2025

*Molecular Psychiatry*

Molecular Psychiatry1380-025

doi: 10.1038/s41380-025-03119-5
20 Meta

Shahinfar, H., et al2025

A systematic review and dose-response meta-analysis of omega-3 supplementation on cognitive function

Scientific Reports1598-025

doi: 10.1038/s41598-025-16129-8
21 Journal

Satizabal, C. L., et al2022

Association of red blood cell omega-3 fatty acids with MRI markers and cognitive function in midlife (Framingham Heart Study)

Neurology

doi: 10.1212/WNL.0000000000201296
22 Journal

Stonehouse, W., et al2013

DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial

American Journal of Clinical Nutrition97(5) · 1134–1143

doi: 10.3945/ajcn.112.053371
23 Journal

Liao, Y., et al2019

Efficacy of omega-3 PUFAs in depression: a meta-analysis

Translational Psychiatry9(1) · 1398-019

doi: 10.1038/s41398-019-0515-5
24 Meta

Bafkar, N., et al2024

Efficacy and safety of omega-3 fatty acids supplementation for anxiety symptoms: a systematic review and dose-response meta-analysis

BMC Psychiatry2888-024

doi: 10.1186/s12888-024-05881-2
25 Meta

Dighriri, I. M., et al2022

Effects of omega-3 polyunsaturated fatty acids on brain functions: a systematic review

Cureus14(10)

doi: 10.7759/cureus.30091
26 Journal

Loong, S., et al2023

Omega-3 fatty acids, cognition, and brain volume in older adults

Brain Sciences13(9)

doi: 10.3390/brainsci13091278
27 Journal

Kang, J. H., et al2022

Marine n-3 fatty acids and cognitive change among older adults in the VITAL randomized trial

Alzheimer's & Dementia: Translational Research8(1)

doi: 10.1002/trc2.12288
28 Review

New perspectives on randomized controlled trials with omega-3 fatty acid supplements and cognition: a scoping review2022

*Prostaglandins, Leukotrienes and Essential Fatty Acids*

Prostaglandins, Leukotrienes and Essential Fatty Acids

doi: 10.1016/j.plefa.2022.102470
29 Review

Omega-3 polyunsaturated fatty acids and cognitive decline in adults with non-dementia or mild cognitive impairment: an overview of systematic reviews2025

*Nutrients*, 17(18), 3002

Nutrients17(18)

doi: 10.3390/nu17183002
30 Journal

Thomas, A., et al2021

Blood polyunsaturated omega-3 fatty acids, brain atrophy, cognitive decline, and dementia risk

Alzheimer's & Dementia17(3) · 432–441

doi: 10.1002/alz.12195
31 Cohort

The relationship of omega-3 fatty acids with dementia and cognitive decline: evidence from prospective cohort studies2023

*American Journal of Clinical Nutrition*, 117(5), 1096–1109

American Journal of Clinical Nutrition117(5) · 1096–1109

doi: 10.1016/j.ajcnut.2023.01.020
32 Journal

Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease2008

*Nature Reviews Neurology*

Nature Reviews Neurology

doi: 10.1038/ncpneuro1044
33 Journal

Associations of fish oil supplementation with incident dementia: evidence from the UK Biobank2022

*Frontiers in Neuroscience*, 16, 910977

Frontiers in Neuroscience

doi: 10.3389/fnins.2022.910977
34 Journal

0
35 Journal

Serum long-chain omega-3 fatty acids and depression among US adults: NHANES 2011–20122021

*Prostaglandins, Leukotrienes and Essential Fatty Acids*

Prostaglandins, Leukotrienes and Essential Fatty Acids2011–2012

doi: 10.1016/j.plefa.2021.102283
36 Review

Richardson, A. J2006

Omega-3 fatty acids in ADHD and related neurodevelopmental disorders

International Review of Psychiatry18(2) · 155–172

doi: 10.1080/09540260600583031
37 Journal

Do omega-3/6 fatty acids have a therapeutic role in children and young people with ADHD?2017

*Journal of Lipids*, 2017, 6285218

Journal of Lipids

doi: 10.1155/2017/6285218
38 Journal

von Schacky, C2021

Importance of EPA and DHA blood levels in brain structure and function

Nutrients13(4)

doi: 10.3390/nu13041074
39 Journal

Comparison of pharmacokinetics of omega-3 fatty acid supplements in monoacylglycerol or ethyl ester in humans: a randomized controlled trial2021

*European Journal of Clinical Nutrition*

European Journal of Clinical Nutrition1430-020

doi: 10.1038/s41430-020-00767-4
40 Journal

Dietary and supplemental long-chain omega-3 fatty acids as moderators of cognitive impairment and Alzheimer's disease2021

*European Journal of Nutrition*, 60(6), 2993–3011

European Journal of Nutrition60(6) · 2993–3011

doi: 10.1007/s00394-021-02655-4
41 Journal

Simopoulos, A. P2002

Importance of the ratio of omega-6/omega-3 essential fatty acids

Biomedicine & Pharmacotherapy56(8) · 365–379

doi: 10.1016/s0753-3322(02)00253-6
42 Journal

N-3 (omega-3) fatty acids: effects on brain dopamine systems and potential role in neuropsychiatric disorders2019

*Frontiers in Physiology*

Frontiers in Physiology

doi: 10.3389/fphys.2019.00547
43 Cohort

Singapore Longitudinal Aging Studies, omega-3 PUFA supplements and cognitive decline2011

*Nutritional Neuroscience*, 14(2), 82–87

Nutritional Neuroscience14(2) · 82–87

doi: 10.1179/1476830511Y.0000000002
44 Journal

Omega-3 fatty acid supplementation and cognitive function: are smaller dosages more beneficial?2014

*International Journal of Molecular Sciences*. PMC: PMC4179753.

International Journal of Molecular Sciences
45 Journal

Plasma omega-3 PUFA and white matter mediated executive decline in older adults2013

*Frontiers in Aging Neuroscience*, 5, 92

Frontiers in Aging Neuroscience

doi: 10.3389/fnagi.2013.00092

The Omega-3 Brain Science That Most Advice Gets Wrong.

The brain evolved inside a dietary ratio industry destroyed

The Molecular Architecture of a Fat-Dependent Brain

Five Studies That Define the Omega-3 Brain Debate

The hero study finds SMD 0.98 attention improvement.